Palisade Bio Participates in Virtual Investor “What This Means” Segment
Palisade Bio (NASDAQ: PALI) has released a Virtual Investor 'What This Means' segment featuring Dr. Joerg Heyer, Head of Translational Science and Medicine. The segment focuses on the company's recent positive preclinical data for their lead product candidate, PALI-2108, which is being developed for the treatment of Ulcerative Colitis (UC).
The preclinical data was previously presented at the 2025 Crohn's and Colitis Congress. Dr. Heyer discusses the implications of these findings for Palisade's UC development program. The virtual segment is now available for viewing, along with other Virtual Investor events.
Palisade Bio (NASDAQ: PALI) ha pubblicato un segmento Virtual Investor intitolato 'Cosa Significa'. In questo segmento, il Dr. Joerg Heyer, Responsabile della Scienza Traslazionale e della Medicina, discute i recenti dati preclinici positivi per il loro principale candidato terapeutico, PALI-2108, attualmente in fase di sviluppo per il trattamento della Colite Ulcerosa (CU).
I dati preclinici erano stati precedentemente presentati al Congresso di Crohn e Colite 2025. Il Dr. Heyer analizza le implicazioni di queste scoperte per il programma di sviluppo della CU di Palisade. Il segmento virtuale è ora disponibile per la visione, insieme ad altri eventi Virtual Investor.
Palisade Bio (NASDAQ: PALI) ha lanzado un segmento de Virtual Investor titulado 'Qué Significa Esto', con el Dr. Joerg Heyer, Jefe de Ciencia Traslacional y Medicina. El segmento se centra en los recientes datos preclínicos positivos para su principal candidato a producto, PALI-2108, que se está desarrollando para el tratamiento de Colitis Ulcerosa (CU).
Los datos preclínicos se presentaron anteriormente en el Congreso de Crohn y Colitis 2025. El Dr. Heyer discute las implicaciones de estos hallazgos para el programa de desarrollo de CU de Palisade. El segmento virtual ya está disponible para su visualización, junto con otros eventos de Virtual Investor.
팔리세이드 바이오 (NASDAQ: PALI)는 '이것이 의미하는 바'라는 제목의 가상 투자자 세그먼트를 발표했습니다. 이 세그먼트에서는 전이 과학 및 의학 책임자인 Dr. Joerg Heyer가 출연합니다. 이 세그먼트는 양성 전임상 데이터에 초점을 맞추고 있으며, 이는 PALI-2108이라는 주요 제품 후보로, 궤양성 대장염 (UC) 치료를 위해 개발되고 있습니다.
전임상 데이터는 이전에 2025 크론병 및 대장염 학회에서 발표되었습니다. Heyer 박사는 이러한 발견이 팔리세이드의 UC 개발 프로그램에 미치는 의미에 대해 논의합니다. 이 가상 세그먼트는 이제 다른 가상 투자자 이벤트와 함께 시청할 수 있습니다.
Palisade Bio (NASDAQ: PALI) a publié un segment Virtual Investor intitulé 'Ce que cela signifie', avec Dr. Joerg Heyer, Responsable de la Science Translationnelle et de la Médecine. Ce segment se concentre sur les données précliniques positives récentes concernant leur principal candidat produit, PALI-2108, qui est en cours de développement pour le traitement de la Colite Ulcéreuse (CU).
Les données précliniques ont été présentées précédemment lors du Congrès de Crohn et Colite 2025. Dr. Heyer discute des implications de ces résultats pour le programme de développement de la CU de Palisade. Le segment virtuel est désormais disponible pour visionnage, ainsi que d'autres événements Virtual Investor.
Palisade Bio (NASDAQ: PALI) hat ein Virtual Investor-Segment mit dem Titel 'Was das bedeutet' veröffentlicht, in dem Dr. Joerg Heyer, Leiter der translationalen Wissenschaft und Medizin, zu sehen ist. Das Segment konzentriert sich auf die kürzlich veröffentlichten positiven präklinischen Daten für ihren Hauptproduktkandidaten, PALI-2108, der zur Behandlung von Ulzerativer Kolitis (UC) entwickelt wird.
Die präklinischen Daten wurden zuvor auf dem 2025 Kongress für Morbus Crohn und Colitis präsentiert. Dr. Heyer erörtert die Auswirkungen dieser Erkenntnisse auf das UC-Entwicklungsprogramm von Palisade. Das virtuelle Segment ist nun zusammen mit anderen Virtual Investor-Veranstaltungen verfügbar.
- Positive preclinical data reported for lead candidate PALI-2108
- None.
Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC)
Carlsbad, CA, March 04, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor “What This Means” segment.
As part of this segment, Dr. Heyer discussed the Company’s positive preclinical data for its lead product candidate, PALI-2108, which was recently presented at the 2025 Crohn’s and Colitis Congress and what this means for Palisade’s UC development program.
The Virtual Investor “What This Means” segment featuring Palisade Bio is now available here. Additional videos from all Virtual Investor events are available at virtualinvestorco.com.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the Company’s Phase 1b/2a clinical study, indications and anticipated benefits of PALI-2108 and the expected timing of the release of topline data from the Phase 1b/2a clinical study. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company is heavily dependent on the success of PALI-2108, which is in the early stages of clinical development and may not successfully progress through clinical development or receive regulatory approval; preliminary clinical study results or the results from earlier preclinical studies may not be predictive of final or future results and unexpected adverse side effects or inadequate efficacy of PALI-2108 may limit its development, regulatory approval and/or commercialization; the Company needs to raise significant additional funds to support its operations and the continued development of PALI-2108; the timing and outcome of the Company’s current and anticipated clinical studies related to its product candidates; indications of use and estimates about the size and growth potential of the markets for the Company’s product candidates, and its ability to serve those markets, including any potential revenue generated; the Company’s ability to maintain the Nasdaq listing of its securities; the Company’s ability to compete effectively in a competitive industry; the Company’s ability to identify and qualify manufacturers to provide API and manufacture drug product; the Company’s ability to enter into commercial supply agreements; the Company’s ability to attract and retain key scientific or management personnel; the accuracy of the Company’s estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and the impact of any global event on the Company’s business, and operations, and supply. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
What is PALI-2108 and what disease is it targeting?
Where was the preclinical data for PALI-2108 presented?
What stage of development is PALI-2108 currently in?
Who presented the PALI-2108 data in the Virtual Investor segment?
